Diagnosis is normally made from a combination of medical history, physical examination, and laboratory (lab) tests. When someone has symptoms that might be caused by aTTP, doctors will typically do blood tests to help with the diagnosis.
People with aTTP are usually diagnosed in the hospital because of their signs and symptoms. In addition to asking about your symptoms, your doctor is likely to perform lab tests to check the following:
Platelet and red blood cell count
ADAMTS13 enzyme activity levels
The ADAMTS13 ADAMTS13: An enzyme, or protein molecule, needed to prevent the body from making more blood clots than it needs. enzyme does not work as well as it should in people with aTTP. Lab tests can tell your doctor how well your ADAMTS13 is working.
Clots can block blood vessels and damage organs such as the brain, heart, or kidneys. This can cause serious health problems, such as stroke or seizure. Your doctor will perform different tests to check your organ function.
aTTP affects up to 5 people per million (or fewer than 2000 people) in the United States every year. We don’t know exactly what causes aTTP—it can affect anyone.
30 to 50 years old
aTTP usually affects people 30 to 50 years of age, but it can affect people of any age.
aTTP is more likely to affect women than men.
Potential risk factors
Pregnancy, weak immune system (eg, due to cancer or HIV), obesity, African American heritage, and infection.
Do not take CABLIVI if you’ve had an allergic reaction to caplacizumab-yhdp or to any of the ingredients in CABLIVI.
Tell your doctor if you have a medical condition including if you have a bleeding disorder. Tell your doctor about any medicines you take.
Talk to your doctor before scheduling any surgery, medical or dental procedure.
CABLIVI can cause severe bleeding. In clinical studies, severe bleeding adverse reactions of nosebleed, bleeding from the gums, bleeding in the stomach or intestines, and bleeding from the uterus were each reported in 1% of subjects. Contact your doctor immediately if excessive bleeding or bruising occur.
You may have a higher risk of bleeding if you have a bleeding disorder (i.e. hemophilia) or if you take other medicines that increase your risk of bleeding such as anti-coagulants.
CABLIVI should be stopped for 7 days before surgery or any medical or dental procedure. Talk to your doctor before you stop taking CABLIVI.
The most common side effects include nosebleed, headache and bleeding gums.
Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of CABLIVI. Call your doctor for medical advice about side effects.
CABLIVI (caplacizumab-yhdp) is a prescription medicine used for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.